BUSINESS● LOW6d ago · Oct 7, 2026, 1:00 PM
Merck’s injectable Keytruda barred in Europe as Halozyme wins injunction
Seeking Alpha Tech · western europe
Merck's injectable drug Keytruda has been barred in Europe following an injunction won by Halozyme. This development impacts the pharmaceutical market and Merck's product availability in the region.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS20m agoWhy did Hong Kong’s 11 Skies fail and can the megaproject be rescued?South China Morning PostBUSINESS22m agoSingapore third-quarter GDP growth softens from four-year high but beats estimatesCNBC